The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma

被引：14

作者：

Colice, Gene L.

机构：

[1] Washington Hosp Ctr, Pulm Serv, Washington, DC 20010 USA

[2] Washington Hosp Ctr, Crit Care Serv, Washington, DC 20010 USA

[3] Washington Hosp Ctr, Resp Serv, Washington, DC 20010 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 15期

关键词：

asthma; ciclesonide; inhaled corticosteroid;

D O I：

10.1517/14656566.7.15.2107

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ciclesonide is the most recently developed inhaled corticosteroid for the treatment of asthma to enter global markets. It has been formulated as an aerosol solution in a metered dose inhaler with hydrofluoralkane. The mass median aerodynamic diameter of aerosolised ciclesonide is 1 - 2 mu m, providing excellent lung deposition characteristics. Ciclesonide can undergo reversible esterification in the lungs, possibly allowing once-daily dosing, and is highly protein bound, possibly leading to reduced systemic side effects. Clinical trials suggest that ciclesonide effectively controls asthma and has a favourable safety profile.

引用

收藏

页码：2107 / 2117

页数：11

相关论文

共 54 条

[41] Population pharmacokinetics and pharmacodynamics of ciclesonide [J].

Rohatagi, S ;

Arya, V ;

Zech, K ;

Nave, R ;

Hochhaus, G ;

Jensen, BK ;

Barrett, JS .

JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (04) :365-378

[42]

Rohatagi Shashank, 2005, Am J Ther, V12, P201

[43] Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma [J].

Sin, DD ;

Man, SFP .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (14) :1591-1595

[44]

SKONER D, 2006, P AM THORAC SOC, V3, pA3024

[45] In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide [J].

Stoeck, M ;

Riedel, R ;

Hochhaus, G ;

Häfner, D ;

Masso, JM ;

Schmidt, B ;

Hatzelmann, A ;

Marx, D ;

Bundschuh, DS .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 309 (01) :249-258

[46] Inhaled corticosteroids: Impact on asthma morbidity and mortality [J].

Suissa, S ;

Ernst, P .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (06) :937-944

[47] Low-dose inhaled corticosteroids and the prevention of death from asthma. [J].

Suissa, S ;

Ernst, P ;

Benayoun, S ;

Baltzan, M ;

Cai, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (05) :332-336

[48] Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma [J].

Szefler, S ;

Rohatagi, S ;

Williams, J ;

Lloyd, M ;

Kundu, S ;

Banerji, D .

CHEST, 2005, 128 (03) :1104-1114

[49] A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients [J].

Taylor, DA ;

Jensen, MW ;

Kanabar, V ;

Engelstätter, R ;

Steinijans, VW ;

Barnes, PJ ;

O'Connor, BJ .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (01) :237-243

[50]

THOMSON PD, 2006, PHYS DESK REF, P1504

← 1 2 3 4 5 6 →